Search trials – HealthDB

AI · cancer

Намерени 1,748 изпитвания за "cancer" Стр. 34 от 88

Recruiting

Study to Identify Biomarkers of Oral Cavity Cancer Response to Neoadjuvant Immunotherapy Prior to Definitive Surgery

Oral Cavity Cancer

The goal of this clinical trial is to study whether researchers can create a patient-specific tumor system, called a culture vessel, in a timely manner and determine if it can predict how someone will respond to a specific therapy. Participants will: * Undergo a research biopsy * Take pembrolizumab per standard of care prior to surgery

Начало: 15.04.2026 Край: 01.12.2027 Възраст: от 18 г.

United States University of Wisconsin, Madison NCT07343596

Recruiting

A Study of Cardiac Magnetic Resonance Imaging (CMR) for Evaluating Catheter-Associated Right Atrial Clot in People With Cancer

Adult Cancer Patients Right Atrial Clot

The researchers are doing this study to see how well cardiac magnetic resonance imaging (CMR) scans can be used to examine the properties of central venous catheter-associated right atrial clot (RA clot). This could help doctors decide on the best treatment options.

Начало: 15.04.2026 Край: 01.04.2029 Възраст: от 18 г.

United States Memorial Sloan Kettering Cancer Center NCT07549477

Recruiting Phase 2

Multicentre, open-label, phase 1/2 study of LB-208, selective antagonist of the serotonin 5-hydroxytryptamine receptor 1B (HTR1B), in adults with relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r higher-risk (HR) myelodysplastic syndrome (MDS)

Relapse or refractory (r/r) acute myeloid leukaemia (AML) and r/r higher-risk (HR) myelodysplastic syndrome (MDS)

Trial status: Authorised Plasma concentration-time profiles, and PK parameters of LB-208., Response according to the revised European LeukemiaNet (ELN) Response Criteria in AML (Döhner et al., 2022) and revised International Working Group 2023 (IWG 2023) in HR-MDS (Zeidan, Platzbecker, et al., 2023). Response for all patients will be assessed by the site Investigators. Safety, and toxicity will be described by observed frequency and severity graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 5.0., including dose limiting toxicity (DLT) rate, adverse events (AEs), serious adverse events (SAEs), and AEs leading to discontinuation.

Начало: 15.04.2026 Възраст: от 18 г.

Spain Aop Orphan Pharmaceuticals GmbH 2025-523396-38-00

Recruiting Phase 1

A clinical trial to learn about the effects of DAK539 on the blood levels of repaglinide, midazolam, drospirenone, and ethinyl estradiol in people with advanced cancer

Patients with advanced malignancies

Trial status: Authorised

Начало: 14.04.2026 Възраст: от 18 г.

France, Italy, Spain Novartis Pharma AG 2025-521000-22-00

Recruiting Phase 2

A Phase 1/2 open-label, multicenter study of oral GSK5460025 alone or in combination with other anti-cancer agents in adult participants with Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) solid tumors.

Neoplasms Colorectal

Trial status: Authorised Part 1: Plasma concentrations for GSK5460025, Part 1: Area under the concentration-time curve (AUC) for GSK5460025, Part 1: Time to maximum concentration (Tmax) for GSK5460025, Part 1: Number of participants with clinically important changes in laboratory parameters, Electrocardiogram (ECGs), and vital signs per dose level, Part 2: Number of participants with TESAEs and TEAEs by severity, Part 2: Number of participants with TEAEs leading to dosage modifications, Part 2: Number of participants with clinically important changes in laboratory parameters, ECGs, and vital signs, PFS is defined as time from first dose to progressive disease (as assessed per RECIST 1.1 by Investigator assessment) or death from any cause, whichever is earlier, DoR is defined as time from first documented PR or CR to progressive disease (as assessed per RECIST 1.1 by investigator assessment) or death from any cause, whichever is earlier for participants who have achieved a confirmed CR or PR., Part 2: Plasma concentration of GSK5460025 Part 1: Number of participants with dose limiting toxicities (DLTs) per dose level, Part 1: Number of participants with treatment emergent serious adverse events (TESAEs) and treatment emergent adverse events (TEAEs) by severity per dose level, Part 1: Duration of TESAEs and TEAEs per dose level, Part 1: Number of participants with TESAEs and TEAEs by severity per dose level during DLT observation period, Part 1: Number of participants with dosage modifications due to TEAEs per dose level, "Part 2: Objective Response Rate (ORR) ORR is defined as percentage of participants with confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1) by investigator assessment."

Начало: 14.04.2026 Възраст: от 18 г.

Denmark, France, Italy +3 Glaxosmithkline Research & Development Limited 2025-522318-21-00

Recruiting Phase 2

A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina-S) in Participants with Non-Small Cell Lung Cancer

Locally advanced or metastatic Non-Small Cell Lung Cancer

Trial status: Authorised 1.Duration of Response (DOR) per RECIST v1.1 as Assessed by Investigator [Time Frame: Approximately 4 years], 2.Disease Control Rate (DCR) per RECIST v1.1 as Assessed by Investigator [Time Frame: Approximately 4 years], 3.Progression-free Survival (PFS) [Time Frame: Approximately 4 years], 4.Overall Survival (OS) [Time Frame: Approximately 4 years], 5.Maximum (Peak) Observed Serum Drug Concentration (Cmax) of Rina-S Related Analytes [Time Frame: Approximately 12 months], 6.Time to Reach Maximum (Peak) Serum Drug Concentration (Tmax) of Rina-S Related Analytes[Time Frame: Approximately 12 months], 7.Number of Participants with Antidrug Antibodies (ADAs) [Time Frame: Approximately 12 months], 8.Number of Participants with Treatment-emergent Adverse Events (TEAEs) [Time Frame: Approximately 4 years] Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as Assessed by Investigator [Time Frame: Approximately 3 years]

Начало: 14.04.2026 Възраст: от 18 г.

Belgium, France, Germany +5 Genmab A/S 2025-522107-18-00

Recruiting

Diagnostic Performance Of 4D Dynamic LAFOV FDG-PET Acquisition for Differentiation of Residual Disease and Post-radiation Inflammation in Head Neck SCC Treated by Radiotherapy.

Head & Neck Squamous Cell Carcinoma

This multicenter prospective observational study will evaluate the value of dynamic FDG-PET LAFOV imaging during the initial therapeutic assessment of a head and neck cancer 3 months after completion of curative radiotherapy.

Начало: 13.04.2026 Край: 13.06.2029 Възраст: от 18 г.

France University Hospital, Brest NCT07417605

Recruiting

RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC

Stage IIB-III NSCLC Sleeve Lobectomy Robotic Surgery Neoadjuvant Chemoimmunotherapy

The goal of this multicenter prospective observational study is to learn about the surgical difficulty and outcomes of robotic-assisted sleeve lobectomy in patients with non-small cell lung cancer (NSCLC) after neoadjuvant chemoimmunotherapy. The main questions it aims to answer are: What is the rate of unsuccessful robotic-assisted sleeve lobectomy after neoadjuvant chemoimmunotherapy? What factors are associated with unsuccessful surgery? How do surgeons subjectively assess intraoperative difficulty across multiple dimensions during these procedures? In this study, unsuccessful surgery is defined as any of the following: conversion to thoracotomy, incomplete (non-R0) resection, or major postoperative complications. Participants who are scheduled to undergo curative-intent robotic-assisted sleeve lobectomy as part of their routine clinical care after neoadjuvant chemoimmunotherapy will be enrolled from multiple centers. Clinical, intraoperative, pathological, and short-term postoperative data will be collected prospectively. In addition, surgeons will be asked to provide a multidimensional subjective assessment of intraoperative difficulty, including factors such as pleural adhesions, hilar fibrosis, nodal matting, fissure completeness, and vascular inflammation or edema, to better characterize the technical challenges of surgery and their association with perioperative outcomes.

Начало: 13.04.2026 Край: 30.05.2027

China, France, Italy Shanghai Chest Hospital NCT07541521

Recruiting

Comparison of the Analgesic Efficacy of Erector Spinae Plane Block in Breast-Conserving Surgery Versus Serratus Anterior Block Combined With Additional Pecto-Intercostal II Block

Pain Management in Breast Surgery Pain After Surgery Regional Anaesthesia

This prospective randomized study will compare the effects of Erector Spinae Plane Block (ESPB) and Serratus Anterior Plane Block combined with Pectoral Nerve Block Type II (SAPB + PECS II) on intraoperative analgesia and postoperative opioid consumption in patients undergoing breast cancer surgery. Seventy patients (ASA I-III, aged 18-75 years) will be randomized into two groups using the sealed envelope method. Ultrasound-guided blocks will be performed preoperatively by the same anesthesiologist, with Group 1 receiving ESPB and Group 2 receiving a combined SAPB + PECS II technique performed through a single skin puncture (single needle entry site) with sequential injections into the two target fascial planes. All patients will undergo surgery under general anesthesia and receive postoperative analgesia via morphine patient-controlled analgesia. Pain scores and total opioid consumption will be statistically analyzed, with p \< 0.05 considered significant.

Начало: 10.04.2026 Край: 31.07.2026 Възраст: 18–75 г.

Turkey (Türkiye) Kayseri City Hospital NCT07368413

Recruiting Phase 1

A Study of HDM2024 in Participants With Advanced Solid Tumors

Advanced Solid Tumors

The goal of this clinical trial is to learn if the study drug can work in advanced cancer patients. The main questions it aims to answer are: * Is the drug safe and tolerable ? * Does the drug exhibit antitumor activity ? Participants will receive the study drug once every three weeks, and imaging-based efficacy assessments will be performed every six weeks.

Начало: 10.04.2026 Край: 28.12.2028 Възраст: 18–75 г.

China Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. NCT07539285

Recruiting Phase 1

AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors

Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)

The primary objectives of this trial are to evaluate the safety profile of AMG 436 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for AMG 436 as monotherapy and in combination with other anti-cancer therapies in participants with MSI-H/dMMR solid tumors.

Начало: 08.04.2026 Край: 28.06.2028 Възраст: 18–99 г. Treatment

Australia, China, Japan +1 Amgen NCT07403721

Recruiting Phase 1

GTB-5550 in Advanced Solid Tumors

Tri-specific Killer Engager Solid Tumor Advanced Solid Tumor

This is a first-in-human Phase 1a/1b trial of a B7-H3-targeted natural killer (NK) cell engager, referred to as a TriSpecific Killer Engager (TriKE), for the treatment of select solid tumor cancers. To be considered for the study, a patient must be 18 years or older, have histologically or cytologically confirmed advanced/metastatic cancer that, based on literature reports, expresses B7-H3 at a high frequency, measurable disease by RECIST 1.1 (exception: mCRPC limited to bone metastasis are exempt from this requirement), meets the disease specific criteria for prior failed therapy, and refractory to, intolerant of, or ineligible for therapy options that are known to provide clinical benefit for their diagnosis.

Начало: 08.04.2026 Край: 01.01.2032 Възраст: от 18 г.

United States Masonic Cancer Center, University of Minnesota NCT07541573

Recruiting Phase 2

ETOP 29-25 START-lung: A multicentre phase II trial of tarlatamab in patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2.

Patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2

Trial status: Authorised Objective response rate (ORR) according to RECIST v1.1, Duration of response (DoR), Disease control rate (DCR), Progression-free survival (PFS) according to RECIST v1.1, Incidence, nature, and severity of adverse events according to CTCAE v5, except for CRS and ICANS, that are graded according to the ASTCT criteria and TLS that are graded according to the Cairo-Bishop classification Overall survival rate at 12 months (12-month OS)

Начало: 08.04.2026 Възраст: от 18 г.

France, Greece, Italy +1 ETOP IBCSG Partners Foundation 2025-522288-13-00

Recruiting Phase 3

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Non-Small Cell Lung Cancer

This study aims to evaluate the efficacy and safety of RC148 combined with platinum-based chemotherapy versus Tislelizumab combined with platinum-based chemotherapy in participants with locally advanced or metastatic Squamous NSCLC who have not received first-line treatment. Participants will: Take RC148 or Tislelizumab combined with platinum-based chemotherapy until the end of the research.

Начало: 03.04.2026 Край: 30.11.2029 Възраст: 18–75 г.

China RemeGen Co., Ltd. NCT07416474

Recruiting

Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix

Prostate Cancer Detection

The study is a prospective, multi-center, single cohort study involving up to 10 urological clinics in the US. After provision of informed consent and prior to the scheduled prostate biopsy (≤30 days), up to 20 mL of whole blood will be collected from each subject. The samples will be blinded and sent to Labcorp for evaluation using the Proclarix® assay. Prostate biopsy will be performed according to standard clinical practice of the urologist (systematic, targeted, or combined biopsy with a transrectal or transperineal approach with or without prior magnetic resonance imaging (MRI)). A minimum of 10 cores are required. Histopathological examination of the biopsy specimen will be performed according to the established local practice. A csPCa is defined as ISUP Grade Group ≥2 detected on biopsy. The assay results will be compared to the biopsy results.

Начало: 03.04.2026 Край: 31.03.2027 Възраст: 40–75 г.

United States Sequenom, Inc. NCT07543757

Recruiting

Preoperative Sleep Quality and Postoperative Outcomes in Breast Surgery

Breast Cancer Postoperative Pain Inflammation

Sleep quality is a key physiological factor influencing immune function, inflammatory response, and pain perception. This prospective observational study aims to evaluate whether preoperative sleep quality predicts postoperative inflammation, pain severity, and analgesic consumption in patients undergoing elective breast cancer surgery. Preoperative sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI). Systemic inflammatory response will be evaluated using the Systemic Immune-Inflammation Index (SII), calculated from routine hematological parameters. Postoperative pain will be assessed using the Visual Analog Scale (VAS), and analgesic consumption will be recorded within the first 24 hours. The study aims to determine whether poor sleep quality is associated with increased inflammatory response, higher pain scores, and greater analgesic requirement.

Начало: 01.04.2026 Край: 15.07.2026 Възраст: 18–70 г.

Turkey (Türkiye) Dr Abdurrahman Yurtaslan Ankara Oncology Training and R NCT07547774

Recruiting Phase 1

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Breast Cancer Ovarian Cancer Endometrial Cancer PIK3CA Mutation +5

This is a phase 1/1b, open-label, multicenter study consisting of sequential parts designed to evaluate the safety, tolerability, and effects pharmacokinetic (PK) profile, and antitumor activity of RGT-490, an investigational oral therapy, in adults with locally advanced or metastatic solid tumors including breast cancer. Participants enrolled in the study have advanced disease that is not amendable to curative treatment and whose tumors harbor alterations in the PI3KCA gene.

Начало: 01.04.2026 Край: 01.10.2028 Възраст: от 18 г.

United States Regor Pharmaceuticals Inc. NCT07524322

Recruiting Phase 2/3

A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma Patients

High-Risk Neuroblastoma

Neuroblastoma is the most common type of solid cancer found outside the brain in young children. Generally, it affects children younger than 5 years old, with the average age when it is found being just 2 years. Most patients have 'high-risk' disease, with spread of the disease to different sites (metastases). This multinational study aims to find out how effective and safe the treatment of a monoclonal anti-GD2 antibody hu14.18K322A (daretabart) is when used together with chemotherapy to treat children and young people who have high-risk neuroblastoma.

Начало: 01.04.2026 Край: 01.03.2031 Възраст: 18–18 г.

United States Renaissance Pharma Ltd. NCT07549321

Recruiting Phase 3

Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma

Colorectal Cancer

This study is being done to answer the main question of: Do patients with colorectal cancer that cannot be removed by surgery, that is treated with two new immunotherapy drugs, botensilimab and balstilimab, live longer? Other important questions include: Is their quality of life better? Do their tumours slow in growth or possibly shrink in size? Are there markers in their tumour or blood that can predict whether they achieve any of these benefits? In addition, the study is done to confirm the safety of these immunotherapy drugs and to determine how long it takes for the body to metabolize them.

Начало: 31.03.2026 Край: 30.06.2029 Възраст: от 18 г.

Canada Canadian Cancer Trials Group NCT07152821

Recruiting Phase 1/2

Early-phase Trial to Assess the Safety and Preliminary Efficacy of BNT3214 in Adults With Advanced Solid Tumors

Advanced Solid Tumor Cancer

This study is the first time the drug BNT3214 (also referred to as PM8102) will be tested in people. It is designed to find out if the drug is safe and how well it works for adults with advanced solid tumors. The study will have three parts. The first two parts (Parts A and B) will focus on testing different amounts of BNT3214 to figure out the best and safest dose. The third part (Part C) will test selected doses of BNT3214 in multiple types of cancer.

Начало: 30.03.2026 Край: 01.10.2030 Възраст: от 18 г. Treatment

Australia, China, Taiwan BioNTech SE NCT07455734

1 … 32 33 34 35 36 … 88